Literature DB >> 31821138

Beyond depression: Other uses for tricyclic antidepressants.

Joanne Schneider1, Mary Patterson1, Xavier F Jimenez2.   

Abstract

Tricyclic antidepressants (TCAs) were originally designed and marketed for treating depression, but over time they have been applied to a variety of conditions, mostly off-label. TCAs can serve as first-line or augmenting drugs for neuropathic pain, headache, migraine, gastrointestinal syndromes, fibromyalgia, pelvic pain, insomnia, and psychiatric conditions other than depression. This article reviews pharmacology, dosing, and safety considerations for these uses.
Copyright © 2019 Cleveland Clinic.

Entities:  

Year:  2019        PMID： 31821138     DOI： 10.3949/ccjm.86a.19005

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  7 in total

Review 1.  Rapid Effects of Vagus Nerve Stimulation on Sensory Processing Through Activation of Neuromodulatory Systems.

Authors:  Charles Rodenkirch; Jason B Carmel; Qi Wang
Journal:  Front Neurosci       Date:  2022-07-05       Impact factor: 5.152

2.  Soporific Effect of Modified Suanzaoren Decoction and Its Effects on the Expression of CCK-8 and Orexin-A.

Authors:  Liang-Hui Zhan; Ying-Jie Dong; Ke Yang; Shan-Shan Lei; Bo Li; Xi Teng; Cong Zhou; Rong Luo; Qiao-Xian Yu; Hai-Ying Jin; Gui-Yuan Lv; Su-Hong Chen
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-16       Impact factor: 2.629

3.  Consecutive Controlled Case Series on Effectiveness of Opipramol in Severe Sleep Bruxism Management-Preliminary Study on New Therapeutic Path.

Authors:  Mieszko Wieckiewicz; Helena Martynowicz; Tomasz Wieczorek; Anna Wojakowska; Katarzyna Sluzalec-Wieckiewicz; Pawel Gac; Rafal Poreba; Grzegorz Mazur; Efraim Winocur; Joanna Smardz
Journal:  Brain Sci       Date:  2021-01-22

4.  Antidepressant drugs act by directly binding to TRKB neurotrophin receptors.

Authors:  Plinio C Casarotto; Mykhailo Girych; Senem M Fred; Vera Kovaleva; Rafael Moliner; Giray Enkavi; Caroline Biojone; Cecilia Cannarozzo; Madhusmita Pryiadrashini Sahu; Katja Kaurinkoski; Cecilia A Brunello; Anna Steinzeig; Frederike Winkel; Sudarshan Patil; Stefan Vestring; Tsvetan Serchov; Cassiano R A F Diniz; Liina Laukkanen; Iseline Cardon; Hanna Antila; Tomasz Rog; Timo Petteri Piepponen; Clive R Bramham; Claus Normann; Sari E Lauri; Mart Saarma; Ilpo Vattulainen; Eero Castrén
Journal:  Cell       Date:  2021-02-18       Impact factor: 41.582

Review 5.  Novel Pharmacological Approaches to the Treatment of Depression.

Authors:  Elias Elias; Ariel Y Zhang; Melissa T Manners
Journal:  Life (Basel)       Date:  2022-01-28

6.  Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients.

Authors:  Johannes Matthaei; Jürgen Brockmöller; Werner Steimer; Konstanze Pischa; Stefan Leucht; Maria Kullmann; Ole Jensen; Typhaine Ouethy; Mladen Vassilev Tzvetkov; Muhammad Rafehi
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810

Review 7.  Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.

Authors:  Elaine Meade; Sarah Hehir; Neil Rowan; Mary Garvey
Journal:  J Fungi (Basel)       Date:  2022-03-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.